Differences in mode of action of (β-lactam antibiotics influence morphology, LPS release and in vivo antibiotic efficacy
Antibiotic mediated release of endotoxin (lipopolysaccharide, LPS) from Gram-negative bacteria is implicated in septic shock. The β-lactam (cell wall active) class, in particular, has been deemed responsible for release of greater quantities of LPS than other classes of antibiotics. However, it is becoming increasingly recognized that variations in the ability to liberate free LPS exist within the β-lactam subclasses. Until recently, LPS-release studies have primarily included the cephalosporin, monobactam, and penicillin β-lactams, but not the carbapenem subclass. We document here that carbapenems significantly liberate less LPS than other β-lactam subclasses, and that disparity in LPS release also occurs within the carbapenems as well (i.e. imipenem vs meropenem). The propensity to release LPS correlates with the cumulative PBP binding affinity of each β-lactam antibiotic regardless of subclass. A direct correlation has been established between antibiotic concentration, frequency of antibiotic exposure, differential LPS release, PBP specificity (morphology, rate of bacterial lysis or cell mass) and antibiotic efficacy in two mouse models of infection. In the first, differences in the pathogenic (endotoxic) potential of potently biologically active smooth LPS (S-LPS) and poorly biologically active rough chemotype LPS (R-LPS) expressing bacteria underscores the in vivo importance of endotoxin in mediating lethality following antibiotic chemotherapy. Endotoxin is, however, not innately toxic and thus its lethal effects are mediated through LPS stimulation of host cells (i.e. macrophages) to produce deleterious levels of cytokines. In the second experimental model, therefore, the toxic effects of antibiotic-liberated endotoxin have been abrogated by pretreatment of mice with carrageenan (CGN) prior to challenge with endotoxin or Gram-negative bacteria. CGN treatment eliminates or markedly reduces the numbers of LPS-responsive mediator cells thus affecting mortality. In both animal models, an in vivo role for LPS is demonstrated through differential changes in antibiotic efficacy (ED 50) in response to differential effects of LPS via modulation of the endotoxic sensitivity/responsiveness of the host. We conclude that antibiotic class, concentration, dosing intervals (timing) and perhaps, method of treatment (i.e. bolus vs infusion) may each be important in the survival of experimental animals severely infected with Gram-negative bacteria.
Top-30
Journals
1
2
3
|
|
Journal of Antimicrobial Chemotherapy
3 publications, 7.32%
|
|
Antimicrobial Agents and Chemotherapy
3 publications, 7.32%
|
|
Journal of Endotoxin Research
2 publications, 4.88%
|
|
Clinical Microbiology and Infection
2 publications, 4.88%
|
|
Journal of Chemotherapy
2 publications, 4.88%
|
|
Infection and Immunity
2 publications, 4.88%
|
|
Animals
1 publication, 2.44%
|
|
Infectious Disease Clinics of North America
1 publication, 2.44%
|
|
International Journal of Antimicrobial Agents
1 publication, 2.44%
|
|
International Journal of Infectious Diseases
1 publication, 2.44%
|
|
Current Therapeutic Research
1 publication, 2.44%
|
|
Microbiology
1 publication, 2.44%
|
|
Biochemical Society Transactions
1 publication, 2.44%
|
|
Critical Care Medicine
1 publication, 2.44%
|
|
Pathogens
1 publication, 2.44%
|
|
Cellular and Molecular Life Sciences
1 publication, 2.44%
|
|
Bulletin of Experimental Biology and Medicine
1 publication, 2.44%
|
|
PLoS Computational Biology
1 publication, 2.44%
|
|
Journal of Infection and Chemotherapy
1 publication, 2.44%
|
|
Journal of Equine Veterinary Science
1 publication, 2.44%
|
|
Peptides
1 publication, 2.44%
|
|
Microbiology and Immunology
1 publication, 2.44%
|
|
Drug Development Research
1 publication, 2.44%
|
|
Pharmacotherapy
1 publication, 2.44%
|
|
Molecular BioSystems
|
Molecular BioSystems, 1, 2.44%
Molecular BioSystems
1 publication, 2.44%
|
FEMS Immunology & Medical Microbiology
1 publication, 2.44%
|
|
Journal of Leukocyte Biology
1 publication, 2.44%
|
|
Integrative Biology (United Kingdom)
1 publication, 2.44%
|
|
Expert Opinion on Emerging Drugs
1 publication, 2.44%
|
|
1
2
3
|
Publishers
1
2
3
4
5
6
7
8
9
|
|
Elsevier
9 publications, 21.95%
|
|
American Society for Microbiology
5 publications, 12.2%
|
|
Wiley
4 publications, 9.76%
|
|
Taylor & Francis
4 publications, 9.76%
|
|
Oxford University Press
4 publications, 9.76%
|
|
MDPI
2 publications, 4.88%
|
|
SAGE
2 publications, 4.88%
|
|
Springer Nature
2 publications, 4.88%
|
|
Royal Society of Chemistry (RSC)
2 publications, 4.88%
|
|
Microbiology Society
1 publication, 2.44%
|
|
Portland Press
1 publication, 2.44%
|
|
Ovid Technologies (Wolters Kluwer Health)
1 publication, 2.44%
|
|
Public Library of Science (PLoS)
1 publication, 2.44%
|
|
Cold Spring Harbor Laboratory
1 publication, 2.44%
|
|
1
2
3
4
5
6
7
8
9
|
- We do not take into account publications without a DOI.
- Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
- Statistics recalculated weekly.